Trial Profile
Variability in systemic exposure to the active metabolite of lisdexamfetamine dimesylate, d-amphetamine, in children with ADHD
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2014
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- 21 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
- 05 Nov 2010 New trial record.